If you have been diagnosed with metastatic non-small cell lung cancer, at HC Cancer Center you can access a phase III clinical trial investigating a new combination of immunotherapy as a possible alternative to conventional chemotherapy.

What does this study consist of?

This study compares an innovative immunotherapy combination (Acasunlimab + Pembrolizumab) against standard chemotherapy (Docetaxel) in patients who have already received previous treatment with immunotherapy and platinum-based chemotherapy.

Who can participate?

• Individuals over 18 years of age
• Patients diagnosed with metastatic non-small-cell lung cancer (stage IV)
• Patients previously treated with PD-1/PD-L1 inhibitor and platinum-based chemotherapy

Cost

There is NO cost to the patient to participate in this trial. All medical procedures are covered by the study sponsor.

Benefits of participating

• Access to state-of-the-art immunological treatments
• Personalised medical care
• Continuous monitoring by specialists